Skip to content

Invasive Coronary Angiography Early in Ischemic Heart Failure

Invasive Coronary Angiography Early in Ischemic Heart Failure (ICE-HF)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04245605
Acronym
ICE-HF
Enrollment
2994
Registered
2020-01-29
Start date
2010-04-01
Completion date
2021-09-30
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure

Keywords

Coronary angiography, Invasive strategy, Myocardial infarction, Troponin, Heart failure

Brief summary

To compare the outcomes of patients with acute heart failure who undergo early coronary angiography vs. usual care

Interventions

PROCEDURECoronary angiography

Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure

Sponsors

Institute for Clinical Evaluative Sciences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Adult patients with acute heart failure, hospitalized in Ontario, Canada, with evidence of possible ischemic heart disease, defined as at least one of: a) prior myocardial infarction, b) troponin elevation, or c) angina.

Exclusion criteria

* Recent myocardial infarction * Coronary angiogram or revascularization within previous 3 months before admission * Nonresidents of Ontario, invalid health card number * HF diagnosed after admission * Admission BNP or NT-proBNP not diagnostic of HF * Died within 14 days of admission * Palliative within 6 months prior to hospital admission * Elevated creatinine concentration * Documented anaphylactic contrast allergy * Ischemic or hemorrhagic stroke within 3 months prior to admission * Highest category of Hospital Frailty Risk Score * Active severe bleeding at time of hospital admission * Absolute platelet count \< 20 * Metastatic cancer

Design outcomes

Primary

MeasureTime frameDescription
Cardiovascular mortality2 yearsDeath due to cardiovascular causes after 14 days in landmark analysis
All-cause mortality2 yearsDeath from any cause after 14 days in landmark analysis

Secondary

MeasureTime frameDescription
All-cause hospital readmission2 yearsReadmissions for all causes after 14 days or hospital discharge in landmark analysis
Heart failure readmission2 yearsReadmissions for heart failure after 14 days or hospital discharge in landmark analysis
Readmission for myocardial infarction2 yearsReadmissions for myocardial infarction after 14 days or hospital discharge in landmark analysis
Rates of revascularization90 daysCoronary revascularization with CABG surgery or PCI procedure

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026